These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 3381257)

  • 1. Decreased incidence of graft-versus-host disease in bone marrow transplantation recipients treated with a combination of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Sundberg B; Bolme P; Brattström C; Gahrton G; Johansen L; Lönnqvist B
    Transplant Proc; 1988 Jun; 20(3):494-8. PubMed ID: 3381257
    [No Abstract]   [Full Text] [Related]  

  • 2. Cyclosporine-A as prevention for graft-versus-host disease in pediatric patients undergoing bone marrow transplants.
    Truog AW; Wozniak SP
    Oncol Nurs Forum; 1990; 17(1):39-44. PubMed ID: 2405360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased incidence and severity of graft-versus-host disease in HLA matched and mismatched marrow recipients of cyclosporine and methotrexate.
    Tollemar J; Ringdén O; Heimdahl A; Lönnqvist B; Sundberg B
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):470-9. PubMed ID: 3291283
    [No Abstract]   [Full Text] [Related]  

  • 4. Combination of cyclosporine and methotrexate for prophylaxis of acute graft versus host disease after allogeneic bone marrow transplantation for leukaemias.
    Mrsić M; Labar B; Bogdanić V; Nemet D; Pavletić Z; Plavsić F; Dobrić I; Kastelan A; Marusić M; Zupancić-Salek S
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():95-6. PubMed ID: 2697416
    [No Abstract]   [Full Text] [Related]  

  • 5. Use of cyclosporine for prevention of graft-versus-host disease after allogeneic bone marrow transplantation.
    Gluckman E; Devergie A; Lokiec F
    Transplant Proc; 1988 Jun; 20(3 Suppl 3):461-9. PubMed ID: 3291282
    [No Abstract]   [Full Text] [Related]  

  • 6. Graft-versus-host-disease prophylaxis for matched unrelated donor bone marrow transplantation: comparison between cyclosporine-methotrexate and cyclosporine-methotrexate-methylprednisolone.
    Leelasiri A; Greer JP; Stein RS; Goodman S; Brandt SA; Edwards JR; Wolff SN
    Bone Marrow Transplant; 1995 Mar; 15(3):401-5. PubMed ID: 7599565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective randomized study of acute graft-v-host disease in 107 patients with leukemia: methotrexate/prednisone v cyclosporine A/prednisone.
    Forman SJ; Blume KG; Krance RA; Miner PJ; Metter GE; Hill LR; O'Donnell MR; Nademanee AP; Snyder DS
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2605-7. PubMed ID: 3079090
    [No Abstract]   [Full Text] [Related]  

  • 8. Prevention of graft-versus-host disease on an individual basis.
    Aschan J; Ringdén O; Andström E; Ljungman P; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1823-4. PubMed ID: 8030155
    [No Abstract]   [Full Text] [Related]  

  • 9. Low incidence of severe acute and chronic graft-versus-host disease as a result of prolonged cyclosporine prophylaxis and early aggressive treatment with corticosteroids.
    Ruutu T; Volin L; Elonen E
    Transplant Proc; 1988 Jun; 20(3):491-3. PubMed ID: 3289191
    [No Abstract]   [Full Text] [Related]  

  • 10. A randomized prospective trial comparing cyclosporine and methotrexate given for prophylaxis of graft-versus-host disease after bone marrow transplantation.
    Biggs JC; Atkinson K; Gillett E; Downs K; Concannon A; Dodds A
    Transplant Proc; 1986 Apr; 18(2):253-5. PubMed ID: 3515659
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination prophylactic immunosuppression in bone marrow transplantation.
    Szer J
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3011-2. PubMed ID: 2650415
    [No Abstract]   [Full Text] [Related]  

  • 12. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease.
    Storb R; Deeg HJ; Whitehead J; Farewell V; Appelbaum FR; Beatty P; Bensinger W; Buckner CD; Clift RA; Doney K
    Transplant Proc; 1987 Feb; 19(1 Pt 3):2608-13. PubMed ID: 3547942
    [No Abstract]   [Full Text] [Related]  

  • 13. Risk factors for acute graft-versus-host disease in 325 consecutive bone marrow recipients.
    Hägglund H; Boström L; Ringdén O; Nilsson B; Remberger M
    Transplant Proc; 1994 Jun; 26(3):1821-2. PubMed ID: 8030154
    [No Abstract]   [Full Text] [Related]  

  • 14. Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe acute graft-versus-host disease, chronic graft-versus-host disease, relapse rate or survival after HLA-identical sibling bone marrow transplantation.
    Atkinson K; Downs K
    Bone Marrow Transplant; 1995 Dec; 16(6):755-8. PubMed ID: 8750265
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of four different protocols for prophylaxis against graft-versus-host disease.
    Tollemar J; Ringdén O; Bäckman L; Janossy G; Lönnqvist B; Markling L; Philstedt P; Sundberg B
    Transplant Proc; 1989 Feb; 21(1 Pt 3):3008-10. PubMed ID: 2650414
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.
    Schwinghammer TL; Bloom EJ
    Clin Pharm; 1993 Oct; 12(10):736-61. PubMed ID: 8258255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graft-versus-leukemia effect in allogeneic marrow transplant recipients with acute leukemia is maintained using cyclosporin A combined with methotrexate as prophylaxis. Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
    Ringdén O; Labopin M; Gluckman E; Reiffers J; Vernant JP; Jouet JP; Harrousseau JL; Fiere D; Bacigalupo A; Frassoni F; Gorin NC
    Bone Marrow Transplant; 1996 Nov; 18(5):921-9. PubMed ID: 8932846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up of a randomized trial comparing T-cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients.
    Remberger M; Ringden O; Aschan J; Ljungman P; Lönnqvist B; Markling L
    Transplant Proc; 1994 Jun; 26(3):1829-30. PubMed ID: 8030159
    [No Abstract]   [Full Text] [Related]  

  • 20. [Bone marrow transplantation in pediatric patients: review of progress].
    Inoue S
    Gan To Kagaku Ryoho; 1987 Apr; 14(4):994-1003. PubMed ID: 3551848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.